Akero Therapeutics To Present At Upcoming Conferences In November

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO), a biotechnology company focused on treatments for non-alcoholic steatohepatitis (NASH), will present at two investor conferences in November 2020. The 29th Annual Credit Suisse Healthcare Conference is scheduled for November 9 at 1:15 PM EST, and the Jefferies Global Healthcare Conference on November 17 at 1:45 PM EST. Live webcasts will be available on their website, with archived replays following the presentations. Akero is dedicated to reversing the NASH epidemic through innovative medicines, particularly their lead candidate, efruxifermin.

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present at the following investor conferences next month:

• 29th Annual Credit Suisse Healthcare Conference on Monday, November 9^th at 1:15PM EST
• Jefferies Global Healthcare Conference on Tuesday, November 17^th at 1:45PM EST

A live webcast of each presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-upcoming-conferences-in-november-301157248.html

SOURCE Akero Therapeutics, Inc.

FAQ

What are the upcoming conferences Akero Therapeutics will present at in November 2020?

Akero Therapeutics will present at the 29th Annual Credit Suisse Healthcare Conference on November 9 at 1:15 PM EST and the Jefferies Global Healthcare Conference on November 17 at 1:45 PM EST.

Where can I watch Akero Therapeutics' conference presentations?

You can watch the live webcasts of Akero Therapeutics' presentations on their website, and archived replays will also be available afterward.

What is Akero Therapeutics' focus area?

Akero Therapeutics focuses on developing treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders.

What is Akero Therapeutics' lead product candidate?

The lead product candidate of Akero Therapeutics is efruxifermin, which has been evaluated in a Phase 2a clinical trial.